Roche announces positive data from broad blood cancer portfolio at EHA 2022 Congress

Source :: PharmaBiz. June 11, 2022
Publication Year :: 2022
Abstract: Roche announced that it is presenting new long-term follow-up results and subanalyses from clinical trials of its approved therapies, as well as data on investigational medicines from its broad blood [...]

Subjects :: Roche Holding AG -- Product development
Rituxan (Medication) -- Product development
Polivy (Medication) -- Product development
Venclexta (Medication) -- Product development
Product development
Non-Hodgkin lymphomas
Cancer
Chemotherapy
Biotechnology industries -- Product development
Multiple myeloma
Obinutuzumab
Antineoplastic agents -- Product development
Biotechnology industry -- Product development
Non-Hodgkin's lymphomas
Cancer -- Chemotherapy
Antimitotic agents -- Product development

Tools